4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) issued its quarterly earnings data on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ:FDMT traded up $0.05 during midday trading on Friday, hitting $4.53. 1,233,187 shares of the company’s stock traded hands, compared to its average volume of 846,836. The company has a market cap of $209.41 million, a PE ratio of -1.59 and a beta of 2.81. The firm’s fifty day moving average price is $5.22 and its two-hundred day moving average price is $8.59. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25.

Analysts Set New Price Targets

Several research firms have recently issued reports on FDMT. Morgan Stanley reduced their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Leerink Partners dropped their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Chardan Capital decreased their price target on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.